These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7911187)

  • 1. ASCO debates high-dose chemotherapy. American Society of Clinical Oncology.
    Astrow AB
    Lancet; 1994 Jun; 343(8911):1493. PubMed ID: 7911187
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mammary cancerology and gynecology. 35th Congress of the American Society of Clinical Oncology (ASCO) Atlanta (United States), May 1999].
    Mabro M
    Rev Med Interne; 1999 Oct; 20(10):855-7. PubMed ID: 10573720
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II or III breast cancer involving 10 or more axillary lymph nodes (CALGB Protocol 9082). Cancer and Leukemia Group B.
    Hurd DD; Peters WP
    J Natl Cancer Inst Monogr; 1995; (19):41-4. PubMed ID: 7577204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
    Peters WP; Ross M; Vredenburgh JJ; Meisenberg B; Marks LB; Winer E; Kurtzberg J; Bast RC; Jones R; Shpall E
    J Clin Oncol; 1993 Jun; 11(6):1132-43. PubMed ID: 8501500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of very-high-dose chemotherapy with autologous bone marrow transplantation in treatment of breast cancer.
    Dunphy FR; Spitzer G
    J Natl Cancer Inst; 1992 Jan; 84(2):128-9. PubMed ID: 1735880
    [No Abstract]   [Full Text] [Related]  

  • 6. [The 34th Annual Congress of the American Society of Clinical Oncology. 16-19 May 1998, Los Angeles, USA. Breast tumors (I)].
    Conti F
    Clin Ter; 1998; 149(3):171-6. PubMed ID: 9842098
    [No Abstract]   [Full Text] [Related]  

  • 7. Dose-intensive therapy for breast cancer.
    O'Shaughnessy JA; Cowan KH
    JAMA; 1993 Nov; 270(17):2089-92. PubMed ID: 8411576
    [No Abstract]   [Full Text] [Related]  

  • 8. Highlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA.
    Burstein HJ
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):581-3. PubMed ID: 16111459
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical trials referral resource. High priority trials--III. Breast cancer.
    Cheson BD; Ungerleider RS
    Oncology (Williston Park); 1992 Dec; 6(12):46-50. PubMed ID: 1334690
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
    Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
    Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [35th annual meeting of the ASCO. American Society of Clinical Oncology].
    Zelek L; Spielmann M; Metges JP
    Bull Cancer; 1999 Sep; 86(9):779-81. PubMed ID: 10576814
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized trials of high dose chemotherapy for breast cancer.
    Antman KH
    Biochim Biophys Acta; 2001 Mar; 1471(3):M89-98. PubMed ID: 11250065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Report from the 44th Congress of the American Society of Clinical Oncology].
    Baki M
    Magy Onkol; 2008 Dec; 52(4):397-8. PubMed ID: 19068469
    [No Abstract]   [Full Text] [Related]  

  • 15. [Chemotherapy of advanced breast cancer].
    Ogawa M
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):769-74. PubMed ID: 1605652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The era of meta-analyses-based recommendations: how were the Japanese Breast Cancer Society Clinical Practice Guidelines for Systemic Treatment of Breast Cancer established?
    Takano T
    Breast Cancer; 2020 May; 27(3):332-333. PubMed ID: 32342405
    [No Abstract]   [Full Text] [Related]  

  • 17. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out.
    Smith GA; Henderson IC
    Important Adv Oncol; 1995; ():201-14. PubMed ID: 7672807
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast cancer: long-term results.
    Baker WJ; Vukelja SJ; Burrell LM; Lee N; Perry JJ
    Bone Marrow Transplant; 1998 Apr; 21(8):775-8. PubMed ID: 9603400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
    Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
    Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
    Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
    Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.